Advertisement

Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer

  • M. J. Piccart

Abstract

Taxol was identified 22 years ago as the active substance of the bark of the Pacific yew, Taxus brevifolia [1].

Keywords

Ovarian Cancer Vinca Alkaloid Advanced Ovarian Cancer Gynecological Oncology Group Gynecological Oncology Group Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wani, M.C., Taylor, H.L., Wall, M.E. et al (1971) Plant antitumor agents. VL The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325–7.CrossRefGoogle Scholar
  2. 2.
    Schiff, P.B., Fant, J. and Horwitz, S.B. (1979) Promotion of microtubule assembly in vitro by Taxol. Nature 22, 665–7.CrossRefGoogle Scholar
  3. 3.
    Schiff, P.B. and Horwitz, S.B. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77,1561–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Rowinsky, E.K., Cazenave, L.A. and Donehower, R.C. (1990) Taxol: a novel investigational antimicrotubule agent. J. Natl Cancer Inst., 1247–59. Google Scholar
  5. 5.
    McGuire, W.P., Rowinsky, E.K., Rosenhein, N.B. et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273–9.PubMedGoogle Scholar
  6. 6.
    Einzig, A.I., Wiernik, P., Sasloff, J. et al (1990) Phase II study of Taxol in patients with advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol 31, 114Google Scholar
  7. 7.
    Thigpen, T., Blessing, J., Ball, H. et al (1990) Phase II trial of Taxol as second-line therapy for ovarian carcinoma: a gynecologic oncology group study. Proc. Am. Soc. Clin. Oncol 9604.Google Scholar
  8. 8.
    Sarosy, G., Kohn, E., Link, C. et al (1992) Taxol dose intensification in patients with recurrent ovarian cancer.Proc. Am. Soc. Cancer. Res. 11, 226.Google Scholar
  9. 9.
    Lorenz, W., Reichmann, H.J., Schmal, A. et al (1977) Histamine release in dogs by Cremophor EL and its derivatives: oxethy- lated oleic acid is the most effective constituent. Agents and Actions 7, 63–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Taxol Investigator s Brochure (1991) National Cancer Institute, Bethesda, MD.Google Scholar
  11. 11.
    Chabner, B.A. (1991) Taxol. Principles Practice Oncol Updates 5,1–9.Google Scholar
  12. 12.
    Weiss, R.B., Donehower, R.C., Wiernik, P.H. et al (1990) Hypersensitivity reactions from Taxol. J. Clin. Oncol 8,1263–8.PubMedGoogle Scholar
  13. 13.
    New, P., Barohn, R., Gales, T. et al (1991) Taxol neuropathy after long term administration. Proc. Am. Assoc. Cancer Res 32,1226.Google Scholar
  14. 14.
    Rowinsky, E.K., McGuire, W.P., Guarnieri, T. et al (1991) Cardiac disturbances during the administration of Taxol. J. Clin. Oncol 9, 1704–12.PubMedGoogle Scholar
  15. 15.
    Horwitz, S.B. (1992) Mechanisms of Taxol Resistance Proceedings of the Second National Cancer Institute Workshop on Taxol and Taxus, September 23–24, Alexandria, VA.Google Scholar
  16. 16.
    Kirschner, L.S., Greenberger, L.M., Hsu, S.I.H. et al (1992) Biochemical and genetic characterization of the multidrug resistance (MDR) phenotype in murine macrophage-like J774.2 cells. Biochem. Pharmacol 43, 77.PubMedCrossRefGoogle Scholar
  17. 17.
    Denis, J.N., Greene, A.E., Guénard, D. et al (1988) A highly efficient, practical approach to natural Taxol. J. Am. Chem. Soc. 110, 5917–19.CrossRefGoogle Scholar
  18. 18.
    Mangatal, L., Adeline, M.I., Guénard, D. et al (1989) Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 45,4177–90.CrossRefGoogle Scholar
  19. 19.
    Denis, J.N., Correa, A. and Greene, A.E. (1990) An improved synthesis of the Taxol side chain and of RP 56976. J. Organ. Chem. 55,1957–9.CrossRefGoogle Scholar
  20. 20.
    Kumar, N. (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol Chem 256,10435–41.PubMedGoogle Scholar
  21. 21.
    Ringel, I. and Horwitz, S.B. (1991) Studies with RP 56976 (Taxotere): a semi-synthetic analog of Taxol. J. Natl Cancer Inst. 83, 288–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Guéritte-Voegelein, F., Guénard, D., Lavelle, F. et al (1991) Relationships between the structure of Taxol analogues and their antimitotic activity, J. Med. Chem. 34,992–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Peyrot, V., Briand, C., Diaz, J.F. and Andreu, J.M. (1992) Biophysical characterization of the assembly of purified tubulin induced by Taxol and Taxotere (RP56976). Proceedings of the Second Interface Clinical and Laboratory Responses to Anticancer drugs: Drugs and Microtubules 24 April, Marseille.Google Scholar
  24. 24.
    Fromes, Y., Goumon, P., Bissery, M.C. and Fellous, A. (1992) Differential effects of Taxol and Taxotere (RP 56976, NSC 628503) on tau and MAP2 containing microtubules. Proc. Am. Assoc. Cancer Res. 33, 3055.Google Scholar
  25. 25.
    Riou, J.F., Naudin, A., Lavelle, F. (1992) Effects of Taxotere on murine and human cell lines. Biochem. Biophys. Res. Comm. 187,164–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Hanauske, A.R., Degen, D., Hilsenbeck, S.G. et al (1992) Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3,121–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Alberts, D.S., Garcia, D., Fanta, P. et al (1992) Comparative cytotoxicities of Taxol and Taxoterein vitro against fresh human ovarian cancers. Proc. Am. Soc. Clin. Oncol 11, 719.Google Scholar
  28. 28.
    Aapro, M., Braakhuis, B., Dietel, M. et al (1992) Superior activity of Taxotere (Ter) over Taxol (Tol) in vitro. Proc. Am. Soc. Clin. Oncol 33, 3086.Google Scholar
  29. 29.
    Vogel, M.M., Danhauser-Riedl, S., Block, T. et al (1992) Preclinical activity of Taxotere (RP 56976) and Taxol against human tumor colony forming units. Proc. Am. Soc. Clin. Oncol 33, 3115.Google Scholar
  30. 30.
    Bissery, M.C., Guénard, D., Guéritte- Voegelein, F. and Lavelle, F. (1991) Experimental activity of Taxotere (RP 56976, NSC 628 503), a Taxol analogue. Cancer Res 51,4845–52.PubMedGoogle Scholar
  31. 31.
    Harrison, S.D., Dykes, D.J., Shepherd, R.V., et al (1992) Response of human tumor xenographs to Taxotere. Proc. Am. Soc. Clin. Oncol 33,3144.Google Scholar
  32. 32.
    Nicoletti, M.L, Massazza, G., Abbott, B.J. et al (1992) Taxol and Taxotere antitumor activity on human ovarian carcinoma xenografts.Proc. Am. Soc. Clin. Oncol 33,3101.Google Scholar
  33. 33.
    Bissery, M.C., Vrignaud, P., Bayssas, M. and Lavelle, F. (1992) In vivo evaluation of Taxotere (RP 56976, NSC 628 503) in combination with cisplatinum, doxorubicin, or vincristine. Proc. Am. Assoc. Cancer Res. 33,443.Google Scholar
  34. 34.
    Rose, W.C. (1992) Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Second National Cancer Institute Workshop on Taxol and Taxus 23–24 September, Alexandria.Google Scholar
  35. 35.
    Johnson, R.K., Chitnis, M.P., Embrey, W.M. and Gregory, E.B. (1978) In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388. Cancer Treat. Rep. 62,1535–47.PubMedGoogle Scholar
  36. 36.
    Hill, B.T., Whelan, R.D.H., Shellard, S.A., et al (1992) Differential cytotoxic effects of Taxotere in a range of mammalian tumor cell lines in vitro. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy 17–20 March, Amsterdam.Google Scholar
  37. 37.
    Lowe, M.C. and Davis, R.D. (1987) The current toxicology protocol of the National Cancer Institute. In Principles of Cancer Chemotherapy (eds. S.K. Carter and K. Hellman) McGraw Hill, New York, pp. 228–35.Google Scholar
  38. 38.
    Extra, J.M., Rousseau, F., Bruno, R. et al (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short I.V. infusion, every 21 days. Cancer Res. 53,1037–42.PubMedGoogle Scholar
  39. 39.
    Tomiak, E., Piccart, M.J., Kerger, J. et al (1991) A phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous (iv) infusion on a weekly basis. Eur. J. Cancer 27 (Suppl. 2), 1184.Google Scholar
  40. 40.
    Burris, H., Irvin, R., Kuhn, J. et al (1992) A 43. phase I clinical trial of Taxotere as a 6 hour infusion repeated every 21 days in patients with refractory solid tumors. Proc. Am. Soc. Oncol 11, 369.Google Scholar
  41. 41.
    Bissett, D., Cassidy, J., Setanolans, A. et al (1992) Phase I study of Taxotere (RP 56976) administered as a 24 hour infusion.Proc. Am.Assoc. Cancer Res. 33, 3145.Google Scholar
  42. 42.
    Pazdur, R., Newman, R.A., Newman, B.M. et al (1992) Phase I trial of Taxotere: five-day schedule. Cancer Inst 84,1781–8.CrossRefGoogle Scholar
  43. 43.
    Lefevre, D., Riou, J.F., Zhou, D.et al (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell Une: decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.Biochem. Pharmacol 41, 1967–79.PubMedCrossRefGoogle Scholar
  44. 44.
    Piccart, M.J., Gore, M., Ten Bokkel Huinink, W. et al (1993) Taxotere (RP56976, NSC628503): an active new drug for the treatment of advanced ovarian cancer (OVCA). Proc. Am. Soc. Clin. Oncol 12, 258.Google Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • M. J. Piccart

There are no affiliations available

Personalised recommendations